Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acceptability of Fixed-Dose Fenofibrate/Metformin in T2D and Dyslipidemia
NCT00490178Phase 3Completed
- Sponsor
- Solvay
- Start
- Mar 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fenofibrate and metformin in type 2 diabetes mellitus (T2DM) and dyslipidemia, sponsored by Solvay. Primary endpoint: Acceptability of treatment at 4 weeks. Started Mar 2007; status: completed.
02
Drugs
fenofibratemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)dyslipidemia
Beyond the preview
Go deeper on NCT00490178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00490178.